Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.50 |
| ▸ | WNT3A | P56704 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14241376 | 0.87 | SMN1; SMN2 (0.60) | MEN1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL515746 | 0.87 | MEN1 (0.73) | MEN1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL29578705 | 0.87 | MEN1 (0.73) | MEN1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL2091365 | 0.84 | MEN1 (0.60) | MEN1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL662208 | 0.84 | MEN1 (0.60) | MEN1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL3948073 | 0.84 | MEN1 (0.60) | MEN1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL2845183 | 0.82 | HTT (0.67) | MEN1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL29175063 | 0.82 | MEN1 (0.68) | MEN1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL2843386 | 0.82 | ALDH1A1 (0.69) | MEN1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL12780432 | 0.82 | MEN1 (0.59) | MEN1KMT2AKDM4ESMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794535-B1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | COLGATE PALMOLIVE CO (US) | 2016-04-20 | — | — | EP | claimed |
| US-9045397-B2 | Processes for making magnolol analogs | COLGATE-PALMOLIVE COMPANY (US) | 2015-06-02 | — | — | US | claimed |
| US-20140343328-A1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | COLGATE-PALMOLIVE COMPANY (US) | 2014-11-20 | — | — | US | claimed |
| EP-2794535-B1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | COLGATE PALMOLIVE CO (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2794535-B1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | COLGATE PALMOLIVE CO (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9045397-B2 | Processes for making magnolol analogs | COLGATE-PALMOLIVE COMPANY (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045397-B2 | Processes for making magnolol analogs | COLGATE-PALMOLIVE COMPANY (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045397-B2 | Processes for making magnolol analogs | COLGATE-PALMOLIVE COMPANY (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140343328-A1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | COLGATE-PALMOLIVE COMPANY (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343328-A1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | COLGATE-PALMOLIVE COMPANY (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343328-A1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | COLGATE-PALMOLIVE COMPANY (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2794535-A1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | Colgate-Palmolive Company (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013095364-A1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | COLGATE-PALMOLIVE COMPANY (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343328-A1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | REN, ADRB1, ADRB2 | MEN1 209/4885KMT2A 2457/4885KDM4E 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.